RGMP

Communication Services Entertainment

Regnum Corp.

$0.00

-0.00 -0.00% today

Price History

Not enough data

Key Stats

Market Cap

2,295

Avg Volume

EPS

-$0.03

52W High

$0.00

52W Low

$0.00

Div. Yield

0.0%

Valuation

P/B Ratio

-0.00

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(42.0%)

Liquidity & Leverage

Current Ratio

0.27

Quick Ratio

0.25

Total Cash

462,374

Total Debt

1.57M

About

Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.